Pomalidomide-PEG4-C-COOH

Background Introduction

Pomalidomide-PEG4-C-COOH is a versatile E3 ligase ligand-linker conjugate widely employed in the development of PROTACs (Proteolysis Targeting Chimeras). This molecular tool combines pomalidomide, a well-known cereblon (CRBN) E3 ligase ligand, with a PEG4 spacer and a carboxylic acid terminal group for streamlined conjugation. The product enables researchers to efficiently design and synthesize targeted protein degraders for advanced therapeutic research.

Mechanism

The mechanism of action relies on the ability of pomalidomide to bind with high affinity to the CRBN E3 ubiquitin ligase component. Pomalidomide-PEG4-C-COOH serves as a modular building block, where the PEG4 linker provides optimal spatial flexibility and solubility. The carboxylic acid (C-COOH) group at the terminus is chemically reactive, facilitating the attachment to a ligand for a protein of interest via amide bond formation. When conjugated, the PROTAC molecule simultaneously recruits the target protein and CRBN, promoting ubiquitination and subsequent proteasomal degradation of the target.

Applications

Pomalidomide-PEG4-C-COOH is ideal for the rational design and synthesis of cereblon-recruiting PROTACs, molecular glues, and related protein degradation technologies. It is extensively used in drug discovery and chemical biology to induce selective degradation of disease-associated proteins, enabling target validation and preclinical research in oncology, neurodegeneration, and beyond. With its ready-to-conjugate carboxylic acid group and flexible PEG4 chain, this E3 ligase ligand-linker conjugate is a valuable tool for generating customized degraders, accelerating the development of next-generation therapeutics.

Pomalidomide-PEG4-C-COOH is a versatile E3 Ligase Ligand-Linker Conjugate used in PROTACs for targeted protein degradation. It effectively bridges E3 ligases to target proteins, enhancing selectivity and degradation efficiency. The following provides a detailed description of this molecule's linker, ligand, and reactive site, aiding in the selection of appropriate target protein ligands.

Linker: This molecule features a PEG4 linker, offering a moderate length that balances flexibility and rigidity, facilitating optimal orientation and spatial arrangement. Its polyethylene glycol structure enhances solubility and biocompatibility, while the non-cleavable nature ensures stability throughout the degradation process.

Ligand: The ligand component is derived from pomalidomide, a thalidomide analog known for its high affinity to the cereblon E3 ligase. It possesses a glutarimide moiety, crucial for binding specificity, and contributes to the overall efficacy of the PROTAC by ensuring robust interaction with the ligase.

Reactive Site: The carboxylic acid group at the terminal end of the molecule serves as the reactive site, facilitating coupling with the target protein ligand. Recommended reaction types include amide bond formation or esterification, which are reliable for creating stable linkages in the conjugate.

Recommended Target Protein Ligand: An electrophilic warhead, such as an acrylamide or chloroacetamide, is compatible with this molecule, offering the advantage of forming covalent bonds with nucleophilic residues on target proteins. This enhances the specificity and potency of the PROTAC, making it suitable for applications in degrading proteins with accessible cysteine or lysine residues, thus expanding the scope of potential therapeutic targets.